@entity900 therapy for disseminated mixed XXXX .

@entity1 @entity632 @entity137 @entity242 @entity5 @entity900
Eighteen @entity1 with metastatic mixed @entity242 received @entity900 therapy at the University of Texas (UT) M.D. Anderson Hospital and @entity5 Institute at Houston. The dose of @entity900 varied from 75 mg/m2 to 100 mg/m2. Previous therapy included surgery in 11 @entity1 , radiotherapy in two @entity1 , and surgery plus radiotherapy in four @entity1 . One @entity1 had no prior therapy. Seven @entity1 had also received prior chemotherapy with @entity632 . Of 12 @entity1 with measurable disease, one (8%) had a complete response and four (33%) had a partial response for an overall response rate of 42%. The median progression-free survival of @entity1 treated with @entity900 as first- and second-line therapy was 4.5 and 5.5 months, respectively. @entity900 demonstrated moderate activity with mild @entity137 in this group of @entity1 with metastatic mixed mesodermal uterine @entity242 . Further studies including @entity900 -containing combination regimens seem to be warranted.
